A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

NCT00422097 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Ixabepilone, 5 mg/d
DRUG: Ixabepilone, 10 mg/d
DRUG: Ixabepilone, 15 mg/d
DRUG: Ixabepilone, 20 mg/d
DRUG: Ixabepilone, 25 mg/d
DRUG: Ixabepilone, 30 mg/d
DRUG: Ixabepilone, 25 mg, with famotidine
DRUG: Ixabepilone, 25 mg, with food

Sponsor

R-Pharm